

LyLe CLL-konference
25. April 2019
Jan Fredholm
Patient i CLL13 protokollen




M: jfh@dr.dk

T: +45 2030 6762

W: www.blomstermaleren.dk




Disclaimer






Mistanke




Udredning





Diagnose



Kontra & Kontrol







Behandlingskrævede



Omgivelser






Kemo / Gazyvaro / Ibrutinib / Venetoclax
Antistof




Overvejelser






Fordomme



Hovedpræmie




Forsøgsarm GIVE






Gazyvaro / Ibrutinib / Venetoclax




Protocol
CLL13




Rutchebane








Trombocytter;B × 109/L





Lymfocytter;B × 109/L







Neutrofilocytter (segmk.+stavn.);B × 109/L




Vejen til mål



Hard work



Talk Show



LYLE CLL-konference
25. April 2019
Jan Fredholm
Patient i CLL13 protokollen



M: jfh@dr.dk

T: +45 2030 6762

W: www.blomstermaleren.dk

